Michael Nally
Known title: Chief Executive OfficerCIK: 0001763945
Michael Nally's purchase track record
Michael Nally has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/4/2026 | GENB | $240K | +11.5% | +40.6% | +11.6% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| GENB | ▲ Buy | Open Market | 20,000 | $240K | 3/4/2026 | View on chart |
| GENB | ▼ Sell | Other | 658,327 | — | 3/2/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 1, 2026
Generate Biomedicines Doses First Patient in GB-5267 CAR T Trial
Generate Biomedicines announced that the first patient has received the investigational GB-5267 therapy in a first‑in‑human trial at Roswell Park. This marks the first dose of the IL‑18 armored CAR‑T cell product and represents a key step toward clinical development. The announcement signals progress in the company’s pipeline and may influence investor perception of its therapeutic potential.
Generate Biomedicines Doses First Patient in GB-5267 CAR T Trial. Generate Biomedicines announced that the first patient has received the investigational GB-5267 therapy in a first‑in‑human trial at Roswell Park. This marks the first dose of the IL‑18 armored CAR‑T cell product and represents a key step toward clinical development. The announcement signals progress in the company’s pipeline and may influence investor perception of its therapeutic potential.